Zemaira is a prescription drug approved by the Food and Drug Administration (FDA) as maintenance therapy in adults who have clinically evident emphysema due to Alpha-1 antitrypsin (AAT) deficiency, a rare genetic condition. Zemaira is also known by its drug name, alpha1-proteinase inhibitor [human].
Zemaira is an alpha1-proteinase inhibitor, a type of molecule derived from human plasma. Zemaira is believed to work by protecting the lungs from damage.
How do I take it?
Zemaira is administered once a week as an intravenous infusion.
Zemaira comes in vial form and requires reconstitution.
The FDA-approved label for Zemaira lists common side effects including headache, upper respiratory tract infections, cold symptoms, and injection site reactions.
Rare but serious side effects listed for Zemaira can include severe allergic reactions and the potential risk for transmitting infectious agents such as viruses.
For more details about this treatment, visit:
Zemaira – CSL Behring